SG11202002259XA - Pharmaceutical constructs with enhanced binding affinity with albumin - Google Patents

Pharmaceutical constructs with enhanced binding affinity with albumin

Info

Publication number
SG11202002259XA
SG11202002259XA SG11202002259XA SG11202002259XA SG11202002259XA SG 11202002259X A SG11202002259X A SG 11202002259XA SG 11202002259X A SG11202002259X A SG 11202002259XA SG 11202002259X A SG11202002259X A SG 11202002259XA SG 11202002259X A SG11202002259X A SG 11202002259XA
Authority
SG
Singapore
Prior art keywords
albumin
binding affinity
enhanced binding
constructs
pharmaceutical
Prior art date
Application number
SG11202002259XA
Inventor
Hsing-Mao Chu
Chien-Jen Lin
Tse-Wen Chang
Original Assignee
Immunwork Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunwork Inc filed Critical Immunwork Inc
Publication of SG11202002259XA publication Critical patent/SG11202002259XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
SG11202002259XA 2017-09-19 2018-09-19 Pharmaceutical constructs with enhanced binding affinity with albumin SG11202002259XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017102242 2017-09-19
PCT/CN2018/106515 WO2019057087A1 (en) 2017-09-19 2018-09-19 Pharmaceutical constructs with enhanced binding affinity with albumin

Publications (1)

Publication Number Publication Date
SG11202002259XA true SG11202002259XA (en) 2020-04-29

Family

ID=65809543

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002259XA SG11202002259XA (en) 2017-09-19 2018-09-19 Pharmaceutical constructs with enhanced binding affinity with albumin

Country Status (12)

Country Link
US (1) US10993986B2 (en)
EP (1) EP3684414A4 (en)
JP (1) JP6984923B2 (en)
KR (1) KR102396217B1 (en)
CN (2) CN117018216A (en)
AU (1) AU2018336482B2 (en)
CA (2) CA3075670C (en)
IL (1) IL273368B2 (en)
RU (1) RU2753880C1 (en)
SG (1) SG11202002259XA (en)
TW (1) TWI688406B (en)
WO (1) WO2019057087A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020510097A (en) * 2017-03-16 2020-04-02 イミュンワーク インク．Ｉｍｍｕｎｗｏｒｋ Ｉｎｃ． Linker unit and molecular construct containing linker unit
WO2021193951A1 (en) * 2020-03-26 2021-09-30 公益財団法人野口研究所 Sugar compound having polyethylene glycol chain, and precursor of antibody-drug complex
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2073011C1 (en) * 1993-10-20 1997-02-10 Российско-германское совместное предприятие "Константа" Linker for solid phase synthesis of peptides
DE19608665A1 (en) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Novel arylglycine amide derivatives, processes for their preparation and pharmaceutical compositions containing them
MXPA01005562A (en) * 1998-11-03 2003-08-01 Centocor Inc Modified antibodies and antibody fragments with increased duration of activity.
US7872095B2 (en) * 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
CN101041693B (en) * 2007-02-06 2011-08-17 珠海联邦制药股份有限公司 Novel blood sugar lowing polypeptide and uses thereof
JP6006118B2 (en) * 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス GLP-1 analogs and derivatives
EP2654794B8 (en) * 2010-12-22 2020-04-22 Baxalta GmbH Materials and methods for conjugating a water soluble fatty acid derivative to a protein
KR20160075665A (en) * 2013-10-22 2016-06-29 프로린크스 엘엘시 Conjugates of somatostatin and its analogs
EP3077008B1 (en) * 2013-12-06 2023-10-04 Jie Han Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
KR101768446B1 (en) * 2014-03-21 2017-08-17 애니젠 주식회사 Novel Exenatide Analogs and Uses thereof
CA2968141C (en) * 2015-01-16 2020-08-04 Hsing-Mao CHU Molecular constructs with targeting and effector elements
BR112017014194A2 (en) * 2015-01-23 2018-01-09 Novartis Ag synthetic apelin fatty acid conjugates with improved half life
RU2703952C2 (en) * 2015-05-20 2019-10-22 Иммунворк Инк. Molecular structures with targeting and effector elements and methods for use thereof
TWI700291B (en) * 2015-06-22 2020-08-01 美國禮來大藥廠 Glucagon and glp-1 co-agonist compounds
CN108431045B (en) * 2015-09-01 2022-05-13 免疫功坊股份有限公司 Molecular construct for preventing and/or treating thrombosis

Also Published As

Publication number Publication date
AU2018336482A1 (en) 2020-04-02
CA3075670A1 (en) 2019-03-28
US20200222498A1 (en) 2020-07-16
CA3075670C (en) 2022-05-31
CA3151394C (en) 2023-10-03
US10993986B2 (en) 2021-05-04
WO2019057087A1 (en) 2019-03-28
IL273368B2 (en) 2023-07-01
CN117018216A (en) 2023-11-10
KR102396217B1 (en) 2022-05-09
EP3684414A4 (en) 2021-06-09
CN111194223A (en) 2020-05-22
AU2018336482B2 (en) 2021-08-12
KR20200044909A (en) 2020-04-29
IL273368B1 (en) 2023-03-01
TW201922293A (en) 2019-06-16
CA3151394A1 (en) 2019-03-28
TWI688406B (en) 2020-03-21
IL273368A (en) 2020-05-31
JP6984923B2 (en) 2021-12-22
CN111194223B (en) 2023-10-24
JP2021501798A (en) 2021-01-21
EP3684414A1 (en) 2020-07-29
RU2753880C1 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and conjugates thereof
IL267894A (en) Improved serum albumin binders
IL267897A (en) Improved serum albumin binders
IL272064A (en) Binding proteins 1
ZA201804601B (en) Psma binding antibody and uses thereof
IL287291A (en) Rgma binding protein and use thereof
PL3271329T3 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
EP3302570A4 (en) Trimaleimide linkers and uses thereof
HK1253533A1 (en) Cd131 binding proteins and uses thereof
IL273368A (en) Pharmaceutical constructs with enhanced binding affinity with albumin
ZA202003845B (en) Fusion proteins
IL265645A (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
ZA201901862B (en) Modified factor h binding protein
ZA201905544B (en) Modified haemoglobin proteins
IL269477A (en) Il-1r-i binding polypeptide
EP3649159C0 (en) Fusion protein
GB201712792D0 (en) Fusion protein
GB201703049D0 (en) Single-strand binding protein
GB201615588D0 (en) TSLP Binding Proteins
IL266419A (en) Binding peptides